The Endocrine Society publicly welcomed an executive order from the White House led by First Lady Melania Trump that targets expanded research and improved clinical care for women across the lifespan. The Society’s president, Nanette Santoro, MD, told reporters the initiative addresses long-standing neglect and underfunding of women’s health. The statement emphasized a willingness to work with the administration to prioritize research and to close “significant gaps” in knowledge about endocrine and reproductive conditions that disproportionately affect women.
The executive order establishes a new Women’s Health Task Force within the White House and creates a Women’s Health Division inside the National Institutes of Health. The article reported those structures by name and described them as the central components of the administration’s approach to improving outcomes for women and girls at every stage of life. The source did not provide operational details about either entity, such as membership, specific responsibilities, or timelines for deliverables.
The Society singled out a set of endocrine and reproductive conditions for heightened attention: polyendocrine metabolic ovary syndrome (PMOS), menopause, infertility, osteoporosis, thyroid disorders and other endocrine diseases that disproportionately affect women. The Society noted that expanding scientific understanding in these areas could accelerate new treatments and improve patient care. The article did not include new clinical data, diagnostic criteria changes or therapeutic recommendations; it reported the Society’s call for research and funding instead.
The Endocrine Society described itself as a global leader in hormone science and health and framed advocacy as a core activity. Investigators reported the Society works with policymakers, clinicians, researchers and patient advocates to advance research that improves lives. The release stated the Society welcomes collaboration with the White House and aims to help prioritize women’s health research, but it did not list specific collaborative projects or joint initiatives already agreed upon with federal agencies.
The Society and other leading women’s health organizations recently endorsed the National Strategy to Close the Women’s Health Gap, a policy framework that the article said calls for a $20 billion investment to transform women’s health research and care. The Society framed endorsement of the strategy as consistent with its priorities and suggested the new White House action aligns with the strategy’s aims. The article did not outline how the proposed investment would be allocated or which agencies and programs would receive funds.
The news release made several concrete announcements but left numerous operational questions unanswered. The source did not report implementation timelines for the Women’s Health Task Force or the NIH Women’s Health Division, nor did it describe their governance, staffing or metrics for success. The article also did not provide details on how the endorsed $20 billion investment would be funded, distributed, or overseen. Finally, there were no clinical trial programs, grant mechanisms, or specific research priorities beyond the disease areas named. These omissions create clear next questions for clinicians and researchers seeking to translate the initiative into actionable studies and funding opportunities.
Limitations and next steps noted by the Society include the need for concrete, evidence-based planning and sustained funding to address the gaps named in the statement. The Society directed readers to its advocacy page for ongoing priorities and to learn how members can engage, but the article did not report follow-up meetings, memoranda of understanding, or formal timelines between the Society and federal partners. The next public milestones—such as Task Force membership announcements, NIH organizational details, or funding calls—were not specified in the source.